Heart failure (HF) has become a frequent manifestation of cardiovascular disease (CVD) among persons with type 2 diabetes mellitus (1, 2) . Epidemiologic evidence suggests higher hemoglobin A 1c (HbA 1c ), increased obesity, and elevated blood pressure (BP) are risk factors for HF among those with diabetes (3) . Measuring natriuretic peptides as part of risk stratification in persons with diabetes is potentially attractive. Cardiac muscle cells release pro-brain natriuretic peptide (proBNP), which is cleaved into the metabolically active BNP and inactive N-terminal (NT)-proBNP. NT-proBNP is more stable in blood and highly correlated with BNP (4). NT-proBNP has been demonstrated to be a fairly sensitive and specific biomarker for HF (5) (6) (7) . NT-proBNP has also been shown to be predictive of future HF, other cardiovascular events, and mortality (8, 9) , although a recent analysis of an elderly cohort suggests a nonlinear relationship between NT-proBNP levels and incident HF, with increasing risk occuring above 190 pg/ml (10) .
A number of studies have demonstrated that increased BMI is associated with lower BNP and/or NT-proBNP levels (11) (12) (13) (14) (15) , including studies of persons with diabetes (12, 16) . Studies have suggested that the inverse relationship between BMI and BNP is mediated by lean-body mass (17, 18) . The data regarding BNP and HbA 1c are mixed, with reports of no association (19, 20) as well as a negative correlation (21) . These associations are counterintuitive, given the suggested relationship between HbA 1c or BMI and HF. Furthermore, in the non-HF setting, data regarding the effect of medical or lifestyle interventions on BNP from randomized trials and/or among persons with diabetes are very limited. Clarification of the relationship between risk factors for HF and NT-proBNP in those who are overweight or obese and have type 2 diabetes mellitus is required before it could be useful to target HF risk stratification. We investigated the correlates of NT-proBNP in a large sample of adults with type 2 diabetes participating in the Look AHEAD (Action for Health in Diabetes) clinical trial, and determined if a lifestyle Look AHEAD (Action for Health in Diabetes) is a randomized trial determining whether intensive lifestyle intervention (ILI) aimed at long-term weight loss and increased physical fitness reduces cardiovascular morbidity and mortality in overweight and obese individuals with type 2 diabetes compared to control (diabetes support and education, DSE). We investigated the correlates of N-terminal pro-brain natriuretic peptide (NT-proBNP), a biomarker associated with heart failure (HF) risk, in a subsample from 15 of 16 participating centers and tested the hypothesis that ILI decreased NT-proBNP levels. Baseline and 1-year blood samples were assayed for NT-proBNP in a random sample of 1,500 without, and all 628 with, self-reported baseline CVD (cardiovascular disease) (N = 2,128). Linear models were used to assess relationships that log-transformed NT-proBNP had with CVD risk factors at baseline and that 1-year changes in NT-proBNP had with intervention assignment. At baseline, the mean (s.d.) age, BMI, and hemoglobin A 1c (HbA 1c ) were 59.6 (6.8) years, 36.0 kg/m 2 (5.8), and 7.2% (1.1), respectively. Baseline geometric mean NT-proBNP was not different by condition (ILI 53.3 vs. DSE 51.5, P = 0.45), was not associated with BMI, and was inversely associated with HbA 1c . At 1 year, ILI participants achieved an average weight loss of 8.3% compared to 0.7% in DSE. At 1 year, NT-proBNP levels increased to a greater extent in the intervention arm (ILI +21.3% vs. DSE +14.2%, P = 0.046). The increased NT-proBNP associated with ILI was correlated with changes in HbA 1c , BMI, and body composition. In conclusion, among overweight and obese persons with diabetes, an ILI that reduced weight was associated with an increased NT-proBNP. articles epidemiology intervention shown to promote weight loss and improve glycemic control and BP at 1 year impacted NT-proBNP level at follow-up.
Methods and Procedures
The Look AHEAD study is a multicenter, randomized trial to determine, in overweight and obese volunteers with type 2 diabetes, the longterm effects of two study conditions: an intensive lifestyle intervention (ILI) designed to achieve and maintain weight loss by decreased caloric intake and increased physical activity vs. a control condition of diabetes support and education (DSE) on the combined incidence of serious cardiovascular events (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke). Details regarding the design and rationale for the study have been published (22 >11% , BP ≥160/100 mm Hg, triglycerides ≥600 mg/dl, weight >350 pounds, CVD events in the prior 3 months, or recent weight loss. Persons meeting these inclusion criteria were additionally screened with an exercise stress test; those with abnormal results were still potentially eligible for randomization after evaluation by their physician. This research was conducted with the approval of each center's institutional review board and participants provided informed consent. The 1-year results of the study have also been published; briefly, ILI resulted in clinically significant weight loss in people with type 2 diabetes which was associated with improved diabetes control and CVD risk factors (23) .
Participant socio-demographic and medical history characteristics were obtained by self-report, including age, gender, race/ethnicity, education, income, source of medical care, medications, and prior CVD. Prior CVD included history of myocardial infarction, coronary artery bypass, angioplasty/stent procedures, peripheral vascular disease, stroke, stable angina, and class I/II HF. Trained and certified clinic staff measured weight and height with the participants wearing light clothing and without shoes. Systolic BP (SBP) and diastolic BP (DBP) were measured as the average of two seated BPs, obtained 30 s apart after an initial 5 min rest period, using a calibrated device (Dinamap Pro 100; GE Medical Systems, Milwaukee, WI). Hypertension was defined as BP ≥140/90 mm Hg or use of antihypertensive medication. Phlebotomy was performed on fasting participants; specimens were assayed at a central laboratory. HbA 1c was measured by a dedicated ion-exchange high-performance liquid chromatography instrument. Measurements of fasting lipids were performed enzymatically using methods standardized to the Centers for Disease Control and Prevention reference.
This manuscript is based on a subset of the baseline data set. Participants were from 15 of the 16 clinical sites; those from the Southwest American Indian Center are not included. The complete data set has been described previously (24) . For this ancillary study, we selected a random sample of 1,500 participants without prior CVD at baseline and all 628 participants with prior CVD who met the following criteria: provided consent for future testing of blood and had baseline and 1 year serum samples stored at −70 °C. NT-proBNP was measured using a sandwich electrochemiluminescence immunoassay performed on a Roche Cobas E411 instrument (Roche Diagnostics, Indianapolis, IN). To assess the coefficient of variation, high and low quality controls were run on two consecutive days, 10 replicates in each run. The coefficient of variation for the high quality control was 1.1%, and for the low quality control was 1.2%. For a given participant, both baseline and 1-year NT-proBNP was measured simultaneously in the same batch.
An analysis was also performed on participants from clinics participating in a body composition substudy and had NT-proBNP measured (N = 581). Body composition was measured by dual energy X-ray absorptiometry at baseline and 1 year; the methods utilized by Look AHEAD have been previously published (25) . Dual energy X-ray absorptiometry provides a measurement of fat and fat-free mass, and the fat-free component can be subdivided into bone mineral and lean soft tissue. We utilized the total body fat and total body lean tissue measures in our analyses.
statistical analyses
The distribution of NT-proBNP was right-skewed; thus we performed a log-transformation. To assess pair-wise cross-sectional relationships that baseline NT-proBNP had with continuous variables, linear regression analyses, and graphical displays were utilized; for categorical variables, analysis of variance was utilized. Based on prior literature we expected NT-proBNP to be associated with age, gender, and prior CVD status, and additionally added race/ethnicity as variables for adjustment (Model 1). We selected additional variables for full covariate adjustment as follows. Candidate variables included randomization arm, date of randomization, clinical center, diabetes duration, BMI, HbA 1c , SBP and DBP, antihypertensive, lipid lowering, diabetes medications, smoking status, and renal function. Continuous variables were standardized. Each term was entered into a linear regression with Model 1 variables; those found to be associated with NT-proBNP (P < 0.2) were retained for the final model (Model 2). We assessed for interactions between predictor variables and intervention condition, CVD status, gender, and race/ethnicity. We also assessed whether baseline predictors of NT-proBNP were balanced by condition. To determine the impact of ILI on NT-proBNP level compared to DSE, we examined the distribution of changes between baseline to 1 year in log-transformed NT-proBNP using analysis of covariance A linear regression model was run including change in NT-proBNP as the outcome, and study arm, demographic characteristics, and covariates found to be imbalanced as independent variables. We also examined pair-wise correlations between change in NT-proBNP and change in the main variables affected by the intervention (weight, glucose control, CVD risk factors) in both ILI and DSE arms. To investigate possible mediation, we added change in these variables to our regression models and determined if the intervention effect (i.e., study arm β-coefficient) remained significant. A two-tailed P value of <0.05 was considered significant. All analyses were performed using STATA 11 (Stata, College Station TX).
results
We obtained NT-proBNP measurements in a subsample (n = 2,128) of the entire Look AHEAD trial (1,079 in ILI and 1,049 in DSE). The characteristics of the subsample did not differ from the characteristics of the overall Look AHEAD cohort on age, gender, ethnicity, or BMI (data not shown). By design, this sample was enriched with persons with prior CVD (29.5% in this subsample vs. 14.1% in the overall cohort). The distribution of baseline characteristics did not differ by intervention condition (Table 1 ) with the exception of a marginal difference in HbA 1c . Baseline geometric mean NT-proBNP was 52.4 pg/ml (s.d. = 2.9) and levels did not differ between conditions. Overall 10.9% had NT-proBNP >190 (10.0% in DSE and 11.7% in ILI, P = 0.2).
cross-sectional analyses
NT-proBNP level was positively associated with older age, female gender, SBP, pulse pressure (SBP-DBP), duration of diabetes, use of thiazolidinediones and antihypertensive drugs, urine albumin, and BMI ( Table 2) . Participants with prior CVD had a higher geometric mean NT-proBNP (86.6 pg/ml) compared to those without CVD (42.5 pg/ml) (difference P < 0.001). We observed a negative association between estimated glomerular filtration rate (GFR) and black race/ethnicity and NT-proBNP. No statistically significant association with DBP, HbA 1c , lipid lowering drugs, fitness level, or smoking was articles epidemiology observed. We found no association between date of randomization or clinic and NT-proBNP (data not shown). Model 2 included all variables that had a P value for the association of ≤0.2; thus, we included all the variables considered above except for fitness and smoking. In this model, a 1 s.d. increment of HbA 1c was associated with a 5% lower NT-proBNP level (P = 0.02). The relationships that SBP and DBP had with NT-proBNP were strong, but in opposite directions. Higher albumin excretion associated with higher NT-proBNP; higher estimated GFR (indicating better renal function) was associated with lower NT-proBNP. When substituting pulse pressure for SBP and DBP, a standard deviation increment of pulse pressure was associated with +13% relative difference in NT-proBNP (95% confidence interval 9%, 17%); the estimates associated with other variables did not appreciably change.
There was a significant interaction between HbA 1c and prior CVD (P value for CVD × HbA 1c = 0.008). After adjusting for Model 2 variables, among those without CVD, a standard deviation increment of baseline HbA 1c was associated with a lower level of NT-proBNP (relative difference −8.6%; 95% confidence interval −13%, −4%, P < 0.001). In contrast, among those with CVD, there was no association present between HbA 1c and NT-proBNP (relative difference +2.8%; 95% confidence interval −6%, +11%, P = 0.52). At a given level of HbA 1c , however, NT-proBNP was substantially higher among those with prior CVD (Figure 1) .The other significant interaction was between prior CVD and gender (P = 0.002); among those with CVD there was no difference in NT-proBNP by gender (data not shown). (Figure 2) . The mean increase was greater in the intervention arm: ILI +21.3% vs. DSE +14.2%, relative difference 7.1%, P = 0.046. We examined correlations between change in NT-proBNP in both arms and change in weight, glucose, BP, and lipid parameters ( Table 3) . Of note, there was an inverse relationship between change in weight variables and change in NT-proBNP among ILI participants, as well as between change in glucose in both groups. Adjusting for demographics, prior CVD, and baseline HbA 1c level did not appreciably change the estimated intervention effect (+7.7%, P = 0.03) ( Table 4 , Model 1). There was no evidence for an interaction between intervention arm and prior CVD, HbA 1c , gender, race-ethnicity, or age (all P > 0.1). The increase in NT-proBNP associated with ILI was similar among those with (+7.3%) or without (+7.8%) prior CVD (interaction P = 0.8). Table 4 demonstrates the impact of additionally adjusting for the change in BP, BMI, estimated GFR, HbA 1c , and lipids ( Table 4 , Models 2-6) and for change in all these parameters (Model 7) on the estimate of the intervention effect. Of note, after accounting for the BP changes, there was a larger effect of the intervention on NT-proBNP. In contrast, adjusting for change in BMI, HbA 1c , triglycerides, and high-density lipoprotein resulted in no suggestion of an independent ILI effect. These suggest that the greater increase in NT-proBNP seen in the ILI arm was associated with the greater weight loss and improvement in metabolic parameters (glucose control and triglycerides).
An analysis of the subset with longitudinal measures of body composition revealed that at 1 year, participants in ILI lost more fat mass (−5.3 vs. −0.1 kg, P < 0.001) as well as more lean body mass (−2.6 vs. −0.3 kg, P < 0.001) than DSE. Among this sample, log NT-proBNP increased 25.5% among those in ILI, vs. 13.6% in DSE (difference +11.9%, P = 0.07). Longitudinal change in NT-proBNP was strongly associated with change in body composition. A 1 s.d. lower fat mass was associated with 11.1% increased NT-proBNP (P = 0.001), while a 1 s.d. lower lean mass was associated with a 7.7% increased NT-proBNP (P = 0.02). When assessing for a difference in NT-proBNP by study arm and adjusting for baseline HbA 1c , prior CVD status, and change in fat mass, the β-coefficient for arm was +1.3%, P = 0.9, while decreased fat mass remained significant (+11.1% per s.d., P = 0.004). When adjusting for baseline HbA 1c , prior CVD status, and change in lean mass, the β coefficient for arm was +6.4%, P = 0.4, while a decreased fat mass remained associated with increased NT-proBNP (+7.1% per s.d., P = 0.06).
dIscussIon
Among overweight and obese adults with diabetes who participated in a clinical trial, the cross-sectional determinants of increased NT-proBNP level includes older age, female gender, prior CVD, higher SBP, lower DBP, poorer kidney function, longer diabetes duration, and lower HbA 1c . The inverse relationship between HbA 1c and NT-proBNP levels was limited to those without prior CVD. After adjusting for demographic factors, we observed a significant positive association between degree of obesity (as measured by BMI) and baseline NT-proBNP; after full adjustment we found no association.
In longitudinal analyses, an ILI that reduced weight and improved diabetes control and CVD risk factor measures at 1 year, NT-proBNP was increased in both arms, and to a greater degree among ILI participants. The increased NT-proBNP associated with ILI was correlated most closely with changes in HbA 1c , and BMI. In the subanalysis including body composition measures, the change in fat mass was the strongest correlate of the change in NT-proBNP.
There are several strengths to this study. We are not aware of a larger sample of persons with diabetes who had NT-proBNP level assessed in the context of a randomized clinical trial which had beneficial effects on several CVD risk factors. The parent study (Look AHEAD) provided a diverse sample of overweight and obese adults with diabetes, with careful characterization of demographic, anthropometric, clinical parameters, and for a subset, body composition measures. Accordingly, we were able to consider and adjust for potential confounders in the cross-sectional associations between risk factors and NT-proBNP. There are also limitations to our study. By design, Look AHEAD did not enroll persons who were not overweight (limiting the range available to examine the relationship between BMI and NT-proBNP). Also, participants in clinical trials may not be representative of the overall population, which may limit the generalizability of our cross-sectional results. On the other hand, a randomized trial is the ideal setting for assessing relationships between interventions and outcomes. We performed assays of NT-proBNP 5-8 years after the blood was obtained and frozen. It is possible that the duration of storage could alter BNP level; however, we did not find evidence for a relationship between date of study entry and NT-proBNP. Finally, the Look AHEAD trial is ongoing and the cardiovascular outcomes which have occurred are not available; thus we cannot investigate the relationship between increased NT-proBNP and CVD events in this report.
Many of the cross-sectional associations found between NT-proBNP and demographic characteristics (age, gender), prior CVD, BP, and renal function in this sample are consistent with prior findings in both the general population and those with diabetes (26) (27) (28) (29) . While several studies have demonstrated that BMI is negatively associated with BNP and/ or NT-proBNP levels (11) (12) (13) (14) (15) , there are a number of studies limited to persons with diabetes that did not show significant associations (28, 30) . In a cross-sectional study of 185 patients attending an obesity clinic, a history of gastric bypass was associated with an increased NT-proBNP level (31) . Although we observed an interaction between A 1c level and CVD status, those without CVD had substantially lower NT-proBNP levels at a given level of A 1c compared to those with CVD. The clinical significance of these findings remain unclear.
We are not aware of larger samples of patients with diabetes who were randomized to weight loss or a control condition and had NTpro-BNP measurements. These data demonstrate that 1-year change in NT-proBNP is negatively associated with change in BMI, HbA 1c , and triglycerides, and positively associated with change in SBP and estimated GFR. The increased NT-proBNP observed among ILI participants relative to DSE appeared to be more strongly related to changes in BMI and articles epidemiology articles epidemiology HbA 1c . While these relationships remained after adjustment for other factors, these results should be interpreted cautiously because, in fact, changes in weight and risk factors were all interrelated. In a nonrandomized prospective cohort of high coronary heart disease risk participants in a comprehensive lifestyle change program (N = 125, 43% with diabetes) BNP (rather than NT-proBNP) was measured at baseline and 3 months; despite an average 7% weight loss there was a significant increase in BNP (32) . Among 132 obese patients undergoing bariatric surgery experiencing an average weight loss of 27% at 6 months, NT-proBNP increased an average of fivefold over preoperative levels (33) . There are few reports of change in BNP in relationship to diabetes therapy. A nonrandomized study tested BNP at baseline and 1 year in 24 patients with diabetes involved in a multifactorial risk reduction intervention; while HbA 1c decreased from a mean of 7.8-7.1%, participants gained weight. They found no difference in BNP level between baseline and follow-up (34) . In 160 participants of the Steno-2 trial (patients with diabetes and microalbuminuria), high baseline NT-proBNP level was associated with longer diabetes duration, age, higher SBP, and impaired kidney function (but not BMI). Of note, at 2 years, NT-proBNP increased to a similar degree in patients randomly assigned to be intensely managed (lower glucose and BP goals) compared to conventional therapy (20) . It has also been reported that thiazolidinedione initiation increases BNP levels (35, 36) ; in the current study thiazolidinedione use was cross-sectionally associated with a higher NT-proBNP level.
There are several potential explanations for our results. There is a well-described "obesity paradox" with respect to HF in the elderly, that is, that the overweight and obese have lower HF mortality, which would be consistent with the lower BNP levels typically seen with obesity (37) . In one study among HF patients which demonstrated that BMI was negatively associated with NT-proBNP, BMI was more strongly associated with lean-body mass than fat mass, and increased lean-body mass was significantly associated with a lower NT-proBNP (18) . The implication is that BMI leads to misclassification of excess adiposity. In the analyses which included dual energy X-ray articles epidemiology absorptiometry measures, we found evidence that the increased NT-proBNP associated with ILI appeared to be largely due to the decreased fat mass observed, and may also be mediated by a decrease in lean mass. This novel finding suggest that rather than causing a misclassification by BMI, there may be a fundamental, biological relationship between adipose tissue and BNP. There is also evidence that sex hormones (particularly androgens) affect natriuretic peptide levels, with increased testosterone leading to a decreased NT-proBNP (38, 39) . Obesity and diabetes are associated with complex changes in sex hormones; with weight loss androgens may increase in men and decrease in women (40, 41) . However, we do not have data regarding sex hormone levels. The known physiologic actions of BNP include arterial vasodilation, natriuresis, diuresis, and a reduction of the activity of the renin-angiotensin-aldosterone system (which leads to decreased hemodynamic stress) (4). Some have argued that lower natriuretic peptide levels in the obese reflect a BNP deficiency, thus weight loss produces a more physiologically appropriate level (33) . These results are novel due to the rigorous design, large sample, and inclusion of body composition data, and confirm prior observation, nonetheless, our findings remain somewhat puzzling, in the face of evidence that elevated NT-proBNP levels are predictive of adverse CVD events and mortality in the general population (8, 9) as well as specifically those with diabetes (20) . It is possible that the small changes in NT-proBNP seen in this study, among a population with few individuals having an abnormal NT-proBNP level, do not reflect an increased risk of events. Recently, McKie and colleagues suggest that NT-proBNP level within the normal range is not predictive of events in healthy adults (42) . However, healthy was defined as the absence of major HF risk factors including diabetes, hypertension, or prior CVD as well as having a normal echocardiogram. In the nonhealthy comparison group (11% of whom had diabetes) increasing NT-proBNP (even in the normal range) was strongly and independently associated with future cardiovascular events and mortality (42) . One study suggests longitudinal increases in NT-proBNP levels are not benign. NT-proBNP levels were assessed at baseline and 2-3 years later in the Cardiovascular Health Study cohort (community dwelling elderly aged 65 and older; 18% with diabetes). Incident HF and CV death were associated with baseline levels of NT-proBNP >190 pg/ml; additionally those with a 25% increase (including those with an initial NT-proBNP <190) had an approximately twofold increased risk of HF or CV death (10) . Ultimately, it remains unclear if the changes observed reflect normal physiology, or portend unforeseen adverse consequences of a lifestyle intervention in this population.
In conclusion, among overweight and obese persons with diabetes, an ILI that reduced weight and improved glucose control was associated with an increase in NT-proBNP. The main implication is that NT-proBNP levels may be difficult to interpret among those who are obese and have diabetes, and therefore of limited utility for use as a screening test (for subclinical heart disease) or for prediction of future HF or CVD events. Further research, in particular, longitudinal data including CVD events, among those with diabetes and/or obesity would contribute to the understanding of the prognostic significance (if any) of natriuretic peptide levels in overweight and obese adults with diabetes who do not have clinically recognized HF.
